Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » Bruker Reports Tough Third Quarter in First Financial Report as Fully Merged Company

Bruker Reports Tough Third Quarter in First Financial Report as Fully Merged Company

Nov 14, 2003
Premium

In a conference call announcing the results of its first quarter as a fully merged company, Bruker Biosciences reported tough times in x-ray crystallography amid booming mass spec sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Changes to the Lancet's Process

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

Emails Show Pressure on CDC

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

Into One System

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

PLOS Papers on Dilated Cardiomyopathy, Lung Cancer Epigenetics, Pediatric Staphylococcus aureus Infections

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Sponsored by
Illumina

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.